Company: DNLI
Filing Date: 2025-12-10
Form Type: 8-K
Source: 0001628280-25-056363
Chunk: 3

Company: Denali Therapeutics Inc.
Filing Date: 2025-12-10
Form: 8-K
Item: Item 9.01
Chunk 3
---
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

  Exhibit No.      Description                                                                                                                                                                                           
          1.1      Underwriting Agreement, dated as of December 9, 2025, among Denali Therapeutics Inc. and Goldman Sachs & Co. LLC, J. P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as representatives of...  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
          4.1      Form of Pre-Funded Warrant                                                                                                                                                                            
          5.1      Opinion of Wilson Sonsini Goodrich & Rosati                                                                                                                                                           
         23.1      Consent of Wilson Sonsini Goodrich & Rosati (included in Exhibit 5.1)                                                                                                                                 
         99.1      Press Release dated December 10, 2025                                                                                                                                                                 
          104      Cover Page Interactive Data File (formatted as Inline XBRL)                                                                                                                                           

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                    DENALI THERAPEUTICS INC.                                             
  Date:      December 10, 2025      By:                           /s/ Alexander O. Schuth, M. D.         
                                                                  Alexander O. Schuth, M. D.             
                                                                  Chief Operating and Financial Officer